TORONTO, Ontario – February 5, 2007: NeuroMedix Inc. (“NeuroMedix” or the “Company”) (TSXV: NMX) today announced that Dr. D. Martin Watterson has resigned from the Company’s Board of Directors due to time constraints from his academic responsibilities. Dr. Watterson will continue with his role as Chairman of NeuroMedix’s Medical and Scientific Advisory Board (“MSAB”) and will also be a consultant to the Company.

“We would like to express our sincere thanks to Dr. Watterson for the contributions that he has made to NeuroMedix”, said Santo Costa, Chairman of NeuroMedix, “Dr. Watterson has played a significant role in the development of NeuroMedix’s technology and we are honoured that he will continue to contribute through his roles as Chair of the MSAB and a consultant.”

About NeuroMedix:

NeuroMedix is a biotechnology company focused on the development of therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer’s disease, traumatic brain injury, neuropathic pain, age-related macular degeneration and multiple sclerosis. Our therapeutic drug candidates are based on research from a team of leading experts in the field of neuroinflammation at Northwestern University and have been demonstrated to reduce brain inflammation, to protect neuronal cells, and to prevent the loss of cognitive function in an Alzheimer’s disease animal model in mice. Our lead candidate, Minozac has also been shown to reduce inflammation and prevent loss of cognitive function in mice suffering traumatic brain injury. Based on these findings, NeuroMedix is pursuing the development of its lead compound for Alzheimer’s disease and traumatic brain injury in humans. NeuroMedix’s shares are listed on the TSX Venture Exchange under the symbol “NMX”.

For further information visit www.neuromedixinc.com or contact:

Mark Pearson, PhD.
Chief Executive Officer
NeuroMedix Inc.
425-503-5156
mark@neuromedixinc.com

or

Catherine Auld, CA
Chief Financial Officer
NeuroMedix Inc.
416-673-8190
cathy@neuromedixinc.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may include but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.